MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-12-27
Target enrollment:
Participant gender:
Summary
This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in
combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung
cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.